Peter R. Kowey

Q: What Schools Are Affiliated With Peter R. Kowey

Peter R. Kowey is affiliated with the following schools: Boston University, Saint Joseph's University, Stanford University, United States Military Academy, University of Toronto, Thomas Jefferson University, Harvard University, University of Pennsylvania

Peter R. Kowey's AcademicInfluence.com Rankings

Peter R. Kowey

Medical

#1645

World Rank

#2008

Historical Rank

#411

USA Rank

Cardiology

#201

World Rank

#206

Historical Rank

#15

USA Rank

medical Degrees

Peter R. Kowey

Philosophy

#7801

World Rank

#11058

Historical Rank

#1652

USA Rank

Logic

#4915

World Rank

#6253

Historical Rank

#840

USA Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Peter R. Kowey's Degrees

Doctorate Medicine University of Pennsylvania
PhD Physiology University of Pennsylvania

Why Is Peter R. Kowey Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Peter R. Kowey is an American cardiologist and medical researcher. He is Professor of Medicine and Clinical Pharmacology at Jefferson Medical College of Thomas Jefferson University and holds the William Wikoff Smith Chair in Cardiovascular Research at Lankenau Institute for Medical Research.

(See a Problem?)

Peter R. Kowey's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. (1997) (3135)
A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. (2003) (1088)
Effect of Catheter Ablation vs Antiarrhythmic Drug Therapy on Mortality, Stroke, Bleeding, and Cardiac Arrest Among Patients With Atrial Fibrillation: The CABANA Randomized Clinical Trial (2019) (800)
Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation. (2019) (763)
Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. (2007) (611)
Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? (1996) (452)
Screening for Atrial Fibrillation: A Report of the AF-SCREEN International Collaboration (2017) (417)
Consensus recommendations for the management of chronic heart failure: Introduction (1999) (391)
Effect of Epicardial or Biventricular Pacing to Prolong QT Interval and Increase Transmural Dispersion of Repolarization: Does Resynchronization Therapy Pose a Risk for Patients Predisposed to Long QT or Torsade de Pointes? (2003) (369)
Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry. (2016) (360)
Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. (1994) (348)
The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation (2015) (343)
Ventricular repolarization components on the electrocardiogram: cellular basis and clinical significance. (2003) (278)
Rationale and design of a large-scale, app-based study to identify cardiac arrhythmias using a smartwatch: The Apple Heart Study (2018) (277)
Does Tpeak-Tend provide an index of transmural dispersion of repolarization? (2007) (275)
Randomized, Double-Blind Comparison of Intravenous Amiodarone and Bretylium in the Treatment of Patients With Recurrent, Hemodynamically Destabilizing Ventricular Tachycardia or Fibrillation (1995) (272)
Phase 2 Early Afterdepolarization as a Trigger of Polymorphic Ventricular Tachycardia in Acquired Long-QT Syndrome: Direct Evidence From Intracellular Recordings in the Intact Left Ventricular Wall (2001) (263)
Dose-Ranging Study of Intravenous Amiodarone in Patients With Life-Threatening Ventricular Tachyarrhythmias (1995) (237)
Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. (2015) (225)
Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. (1998) (222)
Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients With Atrial Fibrillation (2015) (219)
Incidence of Previously Undiagnosed Atrial Fibrillation Using Insertable Cardiac Monitors in a High-Risk Population: The REVEAL AF Study (2017) (184)
Efficacy and safety of ibutilide fumarate for the conversion of atrial arrhythmias after cardiac surgery. (1999) (180)
Vernakalant Hydrochloride for the Rapid Conversion of Atrial Fibrillation After Cardiac Surgery: A Randomized, Double-Blind, Placebo-Controlled Trial (2009) (179)
The Diagnosis of Cardiac Arrhythmias: A Prospective Multi‐Center Randomized Study Comparing Mobile Cardiac Outpatient Telemetry Versus Standard Loop Event Monitoring (2007) (179)
Impact of obstructive sleep apnea and continuous positive airway pressure therapy on outcomes in patients with atrial fibrillation-Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). (2015) (175)
Differences in Clinical and Functional Outcomes of Atrial Fibrillation in Women and Men: Two-Year Results From the ORBIT-AF Registry. (2016) (166)
Association Between Atrial Fibrillation Symptoms, Quality of Life, and Patient Outcomes: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) (2015) (162)
Real-life observations of clinical outcomes with rhythm- and rate-control therapies for atrial fibrillation RECORDAF (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation). (2011) (161)
International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: Results from the GARFIELD‐AF, ORBIT‐AF I, and ORBIT‐AF II registries (2017) (154)
Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. (2014) (152)
Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. (2011) (152)
Ventricular hypertrophy amplifies transmural repolarization dispersion and induces early afterdepolarization. (2001) (151)
Phase 2 Reentry as a Trigger to Initiate Ventricular Fibrillation During Early Acute Myocardial Ischemia (2004) (149)
Frequency and Outcomes of Reduced Dose Non–Vitamin K Antagonist Anticoagulants: Results From ORBIT‐AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II) (2018) (136)
The HARMONY Trial: Combined Ranolazine and Dronedarone in the Management of Paroxysmal Atrial Fibrillation Mechanistic and Therapeutic Synergism (2015) (135)
Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. (2006) (124)
Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. (2010) (122)
Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). (2014) (111)
The RecordAF study: design, baseline data, and profile of patients according to chosen treatment strategy for atrial fibrillation. (2010) (111)
Early Adoption of Dabigatran and Its Dosing in US Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (2013) (108)
Underrepresentation of women, elderly patients, and racial minorities in the randomized trials used for cardiovascular guidelines. (2014) (107)
Use and Associated Risks of Concomitant Aspirin Therapy With Oral Anticoagulation in Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry (2013) (106)
First experience with a Mobile Cardiac Outpatient Telemetry (MCOT) system for the diagnosis and management of cardiac arrhythmia. (2005) (104)
Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies. (2005) (104)
Electrophysiological Effects of Left Ventricular Hypertrophy: Effect of Calcium and Potassium Channel Blockade (1991) (101)
ECG Repolarization Waves: Their Genesis and Clinical Implications (2005) (99)
Reasons for warfarin discontinuation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). (2013) (98)
Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors. (2013) (98)
Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. (2013) (97)
Sustained arrhythmias in hypertrophic obstructive cardiomyopathy. (1984) (95)
Care Patterns and Outcomes in Atrial Fibrillation Patients With and Without Diabetes: ORBIT-AF Registry. (2017) (92)
Progression of atrial fibrillation in the REgistry on Cardiac rhythm disORDers assessing the control of Atrial Fibrillation cohort: clinical correlates and the effect of rhythm-control therapy. (2012) (90)
Digoxin Use and Subsequent Outcomes Among Patients in a Contemporary Atrial Fibrillation Cohort. (2015) (89)
Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS (2016) (87)
Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS (2016) (87)
Cellular Basis of the T Wave: A Century of Controversy (2009) (85)
Regression of left ventricular hypertrophy with captopril restores normal ventricular action potential duration, dispersion of refractoriness, and vulnerability to inducible ventricular fibrillation. (1997) (85)
Assessing proarrhythmic potential of drugs when optimal studies are infeasible. (2009) (84)
Effect of left ventricular hypertrophy and its regression on ventricular electrophysiology and vulnerability to inducible arrhythmia in the feline heart. (1995) (83)
Atrial fibrillation, anticoagulation, and stroke. (1996) (82)
Risks and Benefits of Anticoagulation in Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry (2013) (82)
Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group. (1995) (81)
Left Ventricular Hypertrophy Decreases Slowly but Not Rapidly Activating Delayed Rectifier Potassium Currents of Epicardial and Endocardial Myocytes in Rabbits (2001) (81)
Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter. (2004) (80)
L‐Type Calcium Current Reactivation Contributes to Arrhythmogenesis Associated with Action Potential Triangulation (2007) (80)
Electrocardiographic Early Repolarization: A Scientific Statement From the American Heart Association (2016) (79)
Effect of Antiarrhythmic Drugs on Defibrillation Threshold: Case Report of an Adverse Effect of Mexiletine and Review of the Literature (1988) (78)
Beta-blocker therapy for long QT syndrome and catecholaminergic polymorphic ventricular tachycardia: Are all beta-blockers equivalent? (2017) (76)
Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: Insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry. (2016) (76)
Clinical Outcome of Patients Who Develop PAF After CABG Surgery (2001) (75)
Cardiac Arrhythmia: Mechanisms, Diagnosis, and Management (2001) (74)
Lack of Concordance Between Empirical Scores and Physician Assessments of Stroke and Bleeding Risk in Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry (2014) (74)
Novel oral anticoagulants and reversal agents: Considerations for clinical development. (2015) (71)
Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group. (1995) (71)
The clinical use of angiotensin-converting enzyme inhibitors. (2004) (68)
Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. (2013) (67)
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry. (2014) (65)
Predictors of adverse outcome among patients with hypertension and coronary artery disease. (2006) (62)
A novel mutation in the KCNH2 gene associated with short QT syndrome. (2011) (61)
Predictors and Prognostic Implications of Incident Heart Failure in Patients With Prevalent Atrial Fibrillation. (2017) (60)
Verapamil-sustained release-based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. (2008) (60)
General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA In Silico Strategy (2019) (59)
Provider Specialty and Atrial Fibrillation Treatment Strategies in United States Community Practice: Findings From the ORBIT‐AF Registry (2013) (58)
A broken heart. (1998) (56)
Factors associated with non–vitamin K antagonist oral anticoagulants for stroke prevention in patients with new‐onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT‐AF II) (2017) (56)
Mexiletine Prevents Recurrent Torsades de Pointes in Acquired Long QT Syndrome Refractory to Conventional Measures. (2015) (56)
Efficacy and Safety of Celivarone, With Amiodarone as Calibrator, in Patients With an Implantable Cardioverter-Defibrillator for Prevention of Implantable Cardioverter-Defibrillator Interventions or Death: The ALPHEE Study (2011) (55)
Association of of Atrial Fibrillation Clinical Phenotypes With Treatment Patterns and Outcomes: A Multicenter Registry Study (2017) (55)
The head-up tilt table test and cardiovascular neurogenic syncope. (1993) (54)
Increasing I(Ks) corrects abnormal repolarization in rabbit models of acquired LQT2 and ventricular hypertrophy. (2002) (53)
Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease. (2016) (52)
Contribution of late sodium current (I(Na-L)) to rate adaptation of ventricular repolarization and reverse use-dependence of QT-prolonging agents. (2011) (52)
Management and outcomes of patients with atrial fibrillation and a history of cancer: the ORBIT-AF registry (2017) (51)
Management and prevention of atrial fibrillation after cardiovascular surgery. (2000) (50)
Association of frailty and cognitive impairment with benefits of oral anticoagulation in patients with atrial fibrillation (2019) (50)
Intravenous amiodarone. (2000) (50)
Heart rate is associated with progression of atrial fibrillation, independent of rhythm (2015) (49)
Health-Related Quality of Life in Patients With Atrial Fibrillation Treated With Rhythm Control Versus Rate Control: Insights From a Prospective International Registry (Registry on Cardiac Rhythm Disorders Assessing the Control of Atrial Fibrillation RECORD-AF) (2014) (48)
Assessment of the Proarrhythmic Potential of the Novel Antiarrhythmic Agent AZD7009 and Dofetilide in Experimental Models of Torsades De Pointes (2005) (48)
Predictors and Prognostic Implications of Incident Heart Failure in Patients With Prevalent Atrial Fibrillation. (2016) (45)
Practice patterns among United States cardiologists for managing adults with atrial fibrillation (from the AFFECTS Registry). (2010) (45)
Generic antiarrhythmics are not therapeutically equivalent for the treatment of tachyarrhythmias. (2000) (45)
Calcium-activated chloride current contributes to action potential alternations in left ventricular hypertrophy rabbit. (2008) (45)
Association of Body Mass Index With Care and Outcomes in Patients With Atrial Fibrillation: Results From the ORBIT-AF Registry. (2016) (44)
Are the novel anticoagulants better than warfarin for patients with atrial fibrillation? (2015) (44)
The calamity of cardioversion of conscious patients. (1988) (44)
Defining Clinically Important Difference in the Atrial Fibrillation Effect on Quality-of-Life Score. (2019) (43)
Patient factors associated with quality of life in atrial fibrillation. (2016) (42)
The Electrocardiographic Manifestations of Arrhythmogenic Right Ventricular Dysplasia (2014) (42)
Heart Rhythm Monitoring Strategies for Cryptogenic Stroke: 2015 Diagnostics and Monitoring Stroke Focus Group Report (2016) (42)
Nitrous Oxide Anesthesia in Patients with Ischemic Chest Discomfort: Effect on Beta‐Endorphins (1987) (42)
Electrophysiological Properties of HBI-3000: A New Antiarrhythmic Agent With Multiple-channel Blocking Properties in Human Ventricular Myocytes (2011) (42)
Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF) (2015) (41)
Value of electrophysiologic testing in patients with previous myocardial infarction and nonsustained ventricular tachycardia. Philadelphia Arrhythmia Group. (1990) (40)
Ventricular transmural repolarization sequence: its relationship with ventricular relaxation and role in ventricular diastolic function. (2008) (40)
L-type calcium current recovery versus ventricular repolarization: preserved membrane-stabilizing mechanism for different QT intervals across species. (2008) (39)
Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm. (2006) (38)
Cardiovascular Safety Outcome Trials: A meeting report from the Cardiac Safety Research Consortium. (2015) (38)
Prevalence, Characteristics, and Outcomes of Valvular Heart Disease in Patients With Atrial Fibrillation: Insights From the ORBIT‐AF (Outcomes Registry for Better Informed Treatment for Atrial Fibrillation) (2017) (37)
Efficacy and safety of prescription omega-3-acid ethyl esters for the prevention of recurrent symptomatic atrial fibrillation: a prospective study. (2009) (37)
Use of evidence-based cardiac prevention therapy among outpatients with atrial fibrillation. (2013) (36)
Rationale and design of REVEAL AF: a prospective study of previously undiagnosed atrial fibrillation as documented by an insertable cardiac monitor in high-risk patients. (2014) (36)
Effect of Atrial Fibrillation on Mortality, Stroke Risk, and Quality-of-Life Scores in Patients With Heart Failure (from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF]). (2017) (36)
Use and Associated Risks of Concomitant Aspirin Therapy with Oral Anticoagulation in Patients with Atrial Fibrillation: Insights from the ORBIT-AF Registry (2013) (36)
Sublingual nifedipine for hypertensive emergencies (1991) (35)
Increased late sodium current in left atrial myocytes of rabbits with left ventricular hypertrophy: its role in the genesis of atrial arrhythmias. (2010) (35)
Dronedarone: A New Treatment for Atrial Fibrillation (2008) (35)
Acquired long QT syndrome in hospitalized patients. (2017) (34)
The burden of proof: The current state of atrial fibrillation prevention and treatment trials. (2017) (34)
Planning the Safety of Atrial Fibrillation Ablation Registry Initiative (SAFARI) as a Collaborative Pan-Stakeholder Critical Path Registry Model: a Cardiac Safety Research Consortium "Incubator" Think Tank. (2010) (34)
Warfarin and aspirin use in atrial fibrillation among practicing cardiologist (from the AFFECTS Registry). (2010) (34)
The QT and Tp-e intervals in left and right chest leads: comparison between patients with systemic and pulmonary hypertension. (2005) (33)
Assessment of drug-induced increases in blood pressure during drug development: report from the Cardiac Safety Research Consortium. (2013) (33)
Efficacy of azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence and absence of structural heart disease. (2006) (32)
Non‐Antiarrhythmic Drugs in Atrial Fibrillation: A Review of Non‐Antiarrhythmic Agents in Prevention of Atrial Fibrillation (2007) (32)
Predictors of progression of recently diagnosed atrial fibrillation in REgistry on Cardiac Rhythm DisORDers Assessing the Control of Atrial Fibrillation (RecordAF)-United States cohort. (2013) (32)
Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]). (2017) (31)
Things that go bang in the night (1992) (30)
Electrical Failure of an ICD Lead due to a Presumed Insulation Defect Only Diagnosed by a Maximum Output Shock (2013) (30)
Influence of intracoronary platelet aggregation on ventricular electrical properties during partial coronary artery stenosis. (1983) (30)
Catheter Ablation of Atrial Fibrillation in U.S. Community Practice—Results From Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) (2015) (30)
Rhythm Control Versus Rate Control and Clinical Outcomes in Patients With Atrial Fibrillation: Results From the ORBIT-AF Registry. (2016) (29)
Antiarrhythmic Drug Therapy for Atrial Fibrillation. (2016) (29)
Interaction Between Propranolol and Propafenone in Healthy Volunteers (1989) (28)
PM101: a cyclodextrin-based intravenous formulation of amiodarone devoid of adverse hemodynamic effects. (2009) (27)
Electrophysiologic effects, clinical efficacy and safety of intravenous and oral nadolol in refractory supraventricular tachyarrhythmias. (1987) (27)
Losartan and end‐organ protection—lessons from the renaal study (2005) (26)
Gender differences in device therapy for malignant ventricular arrhythmias. (1995) (26)
The QT interval as it relates to the safety of non-cardiac drugs (2007) (26)
The Role of Cardiovascular Implantable Electronic Devices in the Detection and Treatment of Subclinical Atrial Fibrillation: A Review (2017) (26)
Heterogeneous distribution of INa-L determines interregional differences in rate adaptation of repolarization. (2015) (25)
Effectiveness of oral propafenone for the prevention of atrial fibrillation after coronary artery bypass grafting. (2004) (25)
The properties of the inward rectifier potassium currents in rabbit coronary arterial smooth muscle cells (1999) (25)
Absence of Oral Anticoagulation and Subsequent Outcomes Among Outpatients with Atrial Fibrillation. (2017) (24)
Drug‐induced Proarrhythmia and Torsade de Pointes: A Primer for Students and Practitioners of Medicine and Pharmacy (2018) (24)
Abstract 2860: Efficacy and Safety of Vernakalant Hydrochloride Injection for the Treatment of Atrial Fibrillation After Valvular or Coronary Artery Bypass Surgery (2007) (24)
B-type natriuretic peptide, disease progression and clinical outcomes in atrial fibrillation (2018) (24)
Cardiovascular Safety During and After Use of Phentermine and Topiramate (2018) (23)
Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR. (2016) (23)
Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines: Findings From ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) (2017) (23)
Regression of LV hypertrophy with captopril normalizes membrane currents in rabbits. (1998) (23)
Use of radionuclide ventriculography for assessment of changes in myocardial performance induced by disopyramide phosphate. (1982) (23)
Disease understanding in patients newly diagnosed with atrial fibrillation (2017) (22)
Family history of atrial fibrillation is associated with earlier-onset and more symptomatic atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. (2016) (22)
Building Castles in the Sky. (2018) (21)
Update on atrial fibrillation. (2017) (21)
Dronedarone (2009) (20)
Case of Polymorphic Ventricular Tachycardia in Diphenhydramine Poisoning (2004) (20)
Effect of alpha-adrenergic receptor stimulation on ventricular electrical properties in the normal canine heart. (1983) (20)
Electrophysiologic effects of left ventricular hypertrophy in the intact cat. (1989) (20)
Azimilide reduces emergency department visits and hospitalizations in patients with an implantable cardioverter-defibrillator in a placebo-controlled clinical trial. (2008) (20)
New horizons in antiarrhythmic therapy: will novel agents overcome current deficits? (2008) (20)
Restoration of Normal Ventricular Electrophysiology in Renovascular Hypertensive Rabbits after Treatment with Losartan (2001) (19)
Effect of the 2014 atrial fibrillation guideline revisions on the proportion of patients recommended for oral anticoagulation. (2015) (19)
What's a Mother to Do? (2012) (19)
Late induction of tachycardia in patients with ventricular fibrillation associated with acute myocardial infarction. (1984) (19)
Cardiovascular Safety Profile of Dapoxetine during the Premarketing Evaluation (2011) (19)
Status of Antiarrhythmic Drug Development for Atrial Fibrillation: New Drugs and New Molecular Mechanisms (2016) (19)
COR-ART: A multicenter, randomized, double-blind, placebo-controlled dose-ranging study to evaluate single oral doses of vanoxerine for conversion of recent-onset atrial fibrillation or flutter to normal sinus rhythm. (2015) (19)
Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF I) Registry (2016) (19)
Resuscitation research and emergency waiver of informed consent. (2000) (18)
Evaluation of ventricular arrhythmias in early clinical pharmacology trials and potential consequences for later development. (2010) (18)
Characteristics of contemporary patients with hypertension and coronary artery disease (2004) (18)
Comparison of QTinno, a fully automated electrocardiographic analysis program, to semiautomated electrocardiographic analysis methods in a drug safety study in healthy subjects. (2009) (18)
Outcomes and Anticoagulation Use After Catheter Ablation for Atrial Fibrillation. (2019) (18)
The effect of bretylium and clofilium on dispersion of refractoriness and vulnerability to ventricular fibrillation in the ischemic feline heart. (1985) (18)
The repetitive extrasystole as an index of vulnerability to ventricular fibrillation during myocardial ischemia in the canine heart. (1983) (18)
ST Segment Elevation and Sudden Cardiac Death: (2000) (17)
Prognostic Significance of Nuisance Bleeding in Anticoagulated Patients With Atrial Fibrillation (2018) (17)
Cardioversion and subsequent quality of life and natural history of atrial fibrillation (2017) (17)
Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillation. (2020) (17)
Physician Stated Atrial Fibrillation Management in Light of Treatment Guidelines: Data From an International, Observational Prospective Survey (2010) (17)
Effectiveness of propranolol added to a type I antiarrhythmic agent for sustained ventricular tachycardia secondary to coronary artery disease. (1990) (17)
Differentiating electrophysiological effects and cardiac safety of drugs based on the electrocardiogram: a blinded validation. (2012) (17)
Evaluation of Toxicity for Heart Failure Therapeutics: Studying Effects on the QT Interval (2010) (17)
Pharmacotherapy for Atrial Fibrillation in Patients With Chronic Kidney Disease: Insights From ORBIT‐AF (2018) (16)
Developing the Safety of Atrial Fibrillation Ablation Registry Initiative (SAFARI) as a collaborative pan-stakeholder critical path registry model: a Cardiac Safety Research Consortium "Incubator" Think Tank. (2010) (16)
Effect of thromboxane synthetase inhibition on vulnerability to ventricular arrhythmia following coronary occlusion. (1986) (16)
Should catheter ablation be the preferred therapy for reducing ICD shocks?: Ventricular tachycardia ablation versus drugs for preventing ICD shocks: role of adjuvant antiarrhythmic drug therapy. (2009) (16)
A randomized, double-blind, placebo-controlled trial assessing the efficacy of S66913 in patients with paroxysmal atrial fibrillation (2018) (16)
A Pharmacokinetic Study of the Combined Administration of Amiodarone and Ximelagatran, an Oral Direct Thrombin Inhibitor (2004) (16)
Programmed electrical stimulation of the heart in coronary artery disease. (1983) (15)
Ablation Versus Drugs: What Is the Best First-Line Therapy for Paroxysmal Atrial Fibrillation? Antiarrhythmic Drugs Are Outmoded and Catheter Ablation Should Be the First-Line Option for All Patients With Paroxysmal Atrial Fibrillation: Con (2014) (15)
The effect of thromboxane inhibition on vulnerability to ventricular fibrillation in the acute and chronic feline infarction models. (1989) (15)
The Role of Potassium (2002) (15)
Hypertrophic cardiomyopathy: Can the noninvasive diagnostic testing identify high risk patients? (2014) (15)
Propafenone for malignant ventricular arrhythmia: an analysis of the literature. (1991) (14)
A Review of Carvedilol Arrhythmia Data in Clinical Trials (2005) (14)
Bioequivalence of 2 Intravenous Amiodarone Formulations in Healthy Participants (2009) (14)
Electrophysiologic Effects of SB-237376: A New Antiarrhythmic Compound with Dual Potassium and Calcium Channel Blocking Action (2003) (14)
Acute Electrophysiologic Effects and Antiarrhythmic/Antifibrillatory Activity of Intravenous Amiodarone in a Chronic Feline Infarction Model (1989) (14)
The Food and Drug Administration decision not to approve the 110 mg dose of dabigatran: give us a way out. (2012) (14)
Effect of procainamide on dispersion of ventricular refractoriness. (1983) (13)
Pharmacokinetics and platelet aggregation inhibitory effects of a novel intravenous formulation of clopidogrel in humans (2012) (13)
Case Studies with the Experts: Management Decisions in Atrial Fibrillation (2008) (13)
Practical Considerations for the Nonvitamin K Antagonist Oral Anticoagulants (2016) (13)
Embolic and Other Adverse Outcomes in Symptomatic Versus Asymptomatic Patients With Atrial Fibrillation (from the ORBIT-AF Registry). (2018) (12)
Pharmacologic and nonpharmacologic options to maintain sinus rhythm: guideline-based and new approaches. (2003) (12)
Atrial fibrillation: pharmacological therapy. (2011) (12)
Regression of LV hypertrophy with captopril normalizes membrane currents in rabbits. (1998) (12)
Vulnerability to ventricular fibrillation in patients with clinically manifest ventricular tachycardia. (1984) (12)
How well does physician risk assessment predict stroke and bleeding in atrial fibrillation? Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). (2016) (12)
Role of antiarrhythmic drugs: frequent implantable cardioverter-defibrillator shocks, risk of proarrhythmia, and new drug therapy. (2011) (12)
The Role of Dronedarone in the Treatment of Atrial Fibrillation/Flutter in the Aftermath of PALLAS (2014) (12)
Effect of gallopamil on electrophysiologic abnormalities and ventricular arrhythmias associated with left ventricular hypertrophy in the feline heart. (1992) (12)
Arrhythmias Other Than Atrial Fibrillation in Those With an Irregular Pulse Detected With a Smartwatch (2021) (12)
Overview of the Management of Atrial Fibrillation: (2003) (12)
Evaluation of the effects of PM101, a cyclodextrin-based formulation of intravenous amiodarone, on blood pressure in healthy humans. (2009) (11)
Drug therapy for atrial fibrillation. (2008) (11)
Overdrive pacing for ventricular tachyarrhythmias: a reassessment. (1983) (11)
Proarrhythmias and antiarrhythmias: two sides of the same coin. (2005) (11)
Comparison of the Cardiac Electrophysiology and General Toxicology of Two Formulations of Intravenous Amiodarone in Dogs (2009) (11)
Mega-epsilon waves on 12-lead ECG--just another case of arrhythmogenic right ventricular dysplasia/cardiomyopathy? (2013) (11)
The Cardiac Safety Research Consortium enters its second decade: An invitation to participate. (2016) (11)
Uses and Limitations of Electrophysiology Studies for the Selection of Antiarrhythmic Therapy (1986) (11)
Long‐term electrocardiographic safety monitoring in clinical drug development: A report from the Cardiac Safety Research Consortium (2017) (11)
Rhythm monitoring strategies in patients at high risk for atrial fibrillation and stroke: A comparative analysis from the REVEAL AF study. (2020) (11)
Shared Decision Making in Atrial Fibrillation: Patient-Reported Involvement in Treatment Decisions. (2020) (11)
Comparison of Patient‐Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT‐AF Registry (2019) (10)
Long-term follow-up of patients requiring intravenous amiodarone to suppress hemodynamically destabilizing ventricular arrhythmias. (2000) (10)
Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation (2020) (10)
Pharmacological Therapy for Rate and Rhythm Control for Atrial Fibrillation in 2017. (2017) (10)
Device Interaction—Antitachycardia Pacemakers and Defibrillators for Sustained Ventricular Tachycardia (1991) (10)
Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation (2017) (10)
Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes (2016) (10)
Results of a curtailed randomized controlled trial, evaluating the efficacy and safety of azimilide in patients with implantable cardioverter‐defibrillators: The SHIELD‐2 trial (2017) (10)
Drug therapy for atrial fibrillation. (2009) (10)
Arrhythmia inducibility and ventricular vulnerability in a chronic feline infarction model. (1985) (10)
Blood Pressure Control and Cardiovascular Outcomes in Patients With Atrial Fibrillation (From the ORBIT-AF Registry). (2019) (10)
The impact of medical malpractice litigation on cardiovascular practice in the US and China. (2014) (10)
Oral Anticoagulant Use Around the Time of Atrial Fibrillation Ablation: A Review of the Current Evidence of Individual Oral Anticoagulant Use for Periprocedural Atrial Fibrillation Ablation Thromboembolic Prophylaxis (2014) (10)
Cardiovascular Safety of the Selective μ-Opioid Receptor Antagonist Naloxegol: A Novel Therapy for Opioid-Induced Constipation (2018) (10)
Unanswered questions in patients with concurrent atrial fibrillation and acute coronary syndrome. (2014) (9)
Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. (2019) (9)
The Thorough QT Study: Is Its Demise on the Horizon? (2014) (9)
Discontinuation rates of warfarin versus direct acting oral anticoagulants in US clinical practice: Results from Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II). (2020) (9)
Ventricular fibrillation during coronary angiography: the precatheterization QT interval. (1987) (9)
Celivarone for Maintenance of Sinus Rhythm and Conversion of Atrial Fibrillation/Flutter (2012) (9)
Influence of site of stimulation on measurement of ventricular vulnerability in the normal and ischemic feline heart. (1984) (9)
Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry (2018) (9)
Current concepts in the management of long QT syndrome (2002) (9)
The Top Ten Fallacies of Nonsustained Ventricular Tachycardia (1997) (9)
Decreased vulnerability to ventricular fibrillation by vasodilator-induced baroreceptor sensitisation. (1983) (8)
Clinical pharmacology of antiarrhythmic agents. (1985) (8)
Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. (2019) (8)
Handbook of cardiac arrhythmia (1996) (8)
Dose-related haemodynamic effects and pharmacokinetics of oral nicorandil in patients evaluated for chest pain. (1994) (8)
Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA2DS2‐VASc Scores: Findings From the ORBIT‐AF I and II Registries (2018) (8)
Effects of Dronedarone Started Rapidly After Amiodarone Discontinuation (2013) (8)
Therapeutic Strategies Following Major, Clinically Relevant Nonmajor, and Nuisance Bleeding in Atrial Fibrillation: Findings From ORBIT‐AF (2018) (8)
Long QT syndrome, cardiovascular anomaly and findings in ECG-guided genetic testing (2014) (8)
Baseline Demographics, Safety, and Patient Acceptance of an Insertable Cardiac Monitor for Atrial Fibrillation Screening: The REVEAL-AF Study. (2017) (8)
The effects of nitroglycerin on intracoronary platelet aggregation and ventricular vulnerability during partial coronary stenosis (1981) (8)
Comparative cost-effectiveness analysis of quinidine, procainamide and mexiletine. (1991) (8)
Effect of an intravenous angiotensin-converting enzyme inhibitor on the electrophysiologic features of normal and hypertrophied feline ventricles. (1996) (8)
Response to Pasquale Santangeli, MD, Luigi Di Biase, MD, PhD, Andrea Natale, MD. (2014) (8)
Making a silk purse out of a sow's ear. (2005) (7)
Incremental prognostic value of renal function for stroke prediction in atrial fibrillation. (2019) (7)
Evidence for a reexcitability gap in man after treatment with type I antiarrhythmic drugs. (1993) (7)
Antiarrhythmic drug therapy for atrial fibrillation. (2014) (7)
A piece of my mind. The silent majority. (2011) (7)
Sudden death secondary to cardiac arrhythmias: mechanisms and treatment strategies (2006) (7)
Pharmacologic therapies for atrial fibrillation. (2005) (7)
Effects of prostacyclin (PGI2) on vulnerability to ventricular fibrillation in the normal and ischemic canine heart. (1982) (7)
Atrial fibrillation: Choosing an antiarrhythmic drug (2006) (7)
Atrial arrhythmias after cardiac surgery: Sisyphus revisited? (1999) (7)
Mineralocorticoid Receptor Antagonism in Patients With Atrial Fibrillation: Findings From the ORBIT‐AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) Registry (2018) (7)
Modulation of arachidonic acid metabolites and vulnerability to ventricular fibrillation during myocardial ischemia in the cat. (1988) (6)
Discordance in investigator-reported and adjudicated sudden death in TIOSPIR (2017) (6)
Adjuvant therapy for atrial fibrillation. (2010) (6)
Sinus Node Dysfunction Is Associated With Higher Symptom Burden and Increased Comorbid Illness: Results From the ORBIT‐AF Registry (2015) (6)
Selection of drugs in pursuit of a rhythm control strategy. (2005) (6)
Design and Rationale of a Phase 2 Study of NeurOtoxin (Botulinum Toxin Type A) for the PreVention of Post-Operative Atrial Fibrillation - The NOVA Study. (2021) (6)
Celivarone in patients with an implantable cardioverter-defibrillator: adjunctive therapy for the reduction of ventricular arrhythmia-triggered implantable cardioverter-defibrillator interventions. (2012) (6)
Efficacy and Safety of Dronedarone in Patients Previously Treated With Other Antiarrhythmic Agents (2014) (6)
Regional Lack of Consistency in the Management of Atrial Fibrillation (from the RECORD-AF Trial). (2017) (5)
Reexamination of the Embolic Stroke of Undetermined Source Concept (2021) (5)
The Second Annual Think Tank on Prevention of Sudden Cardiac Death in the Young: Developing a rational, reliable, and sustainable national health care resource. A report from the Cardiac Safety Research Consortium (2018) (5)
Sunday, 26 August 2012 (2012) (5)
The repetitive extrasystole as an index of vulnerability to ventricular fibrillation during myocardial ischemia (1981) (5)
Effects of captopril treatment of renovascular hypertension on beta-adrenergic modulation of L-type Ca(2+) current. (2000) (5)
INVEST substudies: Design and patient characteristics (2001) (5)
Changes in Management Following Detection of Previously Unknown Atrial Fibrillation by an Insertable Cardiac Monitor (from the REVEAL AF Study). (2019) (5)
Cardiology patient pages. Ambulatory electrocardiographic recording. (2003) (5)
Pharmacological Therapy for Ventricular Arrhythmias: A State-of-the Art Review. (2019) (5)
Propafenone in the treatment of patients with malignant ventricular tachyarrhythmias. (1991) (5)
Efficacy and safety of dronedarone in patients with a prior ablation for atrial fibrillation/flutter: Insights from the ATHENA study (2019) (5)
A Review of percutaneous mechanical support devices and strategies. (2018) (5)
Drug Interactions with Propafenone (1987) (5)
The Unnecessary Pacemaker Controversy Revisited (2002) (5)
Strategies to Reduce Recurrent Shocks Due to Ventricular Arrhythmias in Patients with an Implanted Cardioverter-Defibrillator (2018) (5)
Efficacy of a Centralized, Blended Electronic and Human Intervention to Improve Direct Oral Anticoagulant Adherence: Smartphones to improve rivaroxaban ADHEREnce in Atrial Fibrillation (SmartADHERE) A Randomized Clinical Trial: SmartADHERE rivaroxaban adherence trial. (2021) (4)
OBSTRUCTIVE SLEEP APNEA AND ATRIAL FIBRILLATION: FINDINGS FROM ORBIT-AF (2014) (4)
Effect of site of pacing on dispersion of refractoriness. (1985) (4)
Influence of Kidney Function Estimation Methods on Eligibility for Edoxaban Population Impact of the US Food and Drug Administration's Approach for Its Product Labeling. (2016) (4)
ST segment elevation with ventricular aneurysm: results of encircling endocardial ventriculotomy. (1984) (4)
Drug-induced long-QT syndrome and torsade de pointes: an underrated problem? (2014) (4)
Measurement of Human Ventricular Effective Refractory Periods: Effect of Incremental Versus Decremental Extrastimulation (1990) (4)
Patterns of amiodarone use and outcomes in clinical practice for atrial fibrillation. (2019) (4)
Abstract 16889: Digoxin Use and Subsequent Outcomes Among Patients with and without Heart Failure in a Contemporary Atrial Fibrillation Cohort: Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) (2014) (4)
Potassium channels in cardiac arrhythmias: focus on antiarrhythmic drug action. (1990) (4)
You only get so many heartbeats... (2004) (4)
THE MYTH OF THE STABLE INR PATIENT: RESULTS FROM ORBIT-AF (2015) (3)
Novel Therapeutic Targets for Antiarrhythmic DrugsBillmanGeorge Edward ed. 573 pages. Hoboken, NJ, USA: John Wiley and Sons, Inc, 2010. $149.95. ISBN: 978-0-470-26100-2 (2011) (3)
AIM‐AF: A Physician Survey in the United States and Europe (2022) (3)
LBBB: The ECG Patterns and Cardiac Function in Patients With and Without Coronary Artery Disease (2012) (3)
MANAGEMENT AND OUTCOMES OF PATIENTS WITH ATRIAL FIBRILLATION AND CANCER: THE ORBIT-AF REGISTRY (2016) (3)
Electrophysiologic studies of the ventricle. (1985) (3)
Fast‐Track Training of Nonelectrophysiologists to Implant Defibrillators: Is It Needed? (2006) (3)
RACIAL/ETHNIC DIFFERENCES IN ATRIAL FIBRILLATION SYMPTOMS, TREATMENT PATTERNS, AND OUTCOMES: INSIGHTS FROM OUTCOMES REGISTRY FOR BETTER INFORMED TREATMENT FOR ATRIAL FIBRILLATION (ORBIT-AF) REGISTRY (2015) (3)
Patterns of oral anticoagulation use with cardioversion in clinical practice (2020) (3)
Oral Anticoagulants to Reduce the Risk of Stroke in Atrial Fibrillation: How Should a Clinician Choose? (2013) (3)
Reversal of fortunes: recognizing misplacement of ECG electrodes. (2013) (3)
Cardiovascular Safety of Aclidinium Bromide in COPD: Pooled Results From 3 Placebo-Controlled Studies (2013) (3)
Cardiac Arrhythmias, Pacing and Sudden Death (2017) (3)
Future directions in antiarrhythmic drug therapy for atrial fibrillation. (2006) (3)
How Much Has Malpractice Litigation Altered the Care of Cardiac Rhythm Patients? (2011) (3)
Long-term Cardiovascular Safety of Aclidinium Bromide in Patients With COPD (2013) (3)
Surgical management and mapping of cardiac arrhythmias. (1985) (3)
COMPARISON OF SYMPTOMS AND QUALITY OF LIFE IN ATRIAL FIBRILLATION: RESULTS FROM THE ORBIT-AF REGISTRY (2012) (3)
A COMPARISON OF ATRIAL FIBRILLATION MONITORING STRATEGIES IN PATIENTS AT HIGH RISK FOR ATRIAL FIBRILLATION AND STROKE: RESULTS FROM THE REVEAL AF STUDY (2018) (3)
Discarding the Baby with the Bathwater (2007) (2)
Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation (2020) (2)
Abstract 14: Clinical Characteristics and Treatment Patterns of Medicaid Patients with Atrial Fibrillation: Insights From the ORBIT-AF I Registry (2015) (2)
ORAL ANTICOAGULANT SELECTION IN COMMUNITY PATIENTS WITH NEW-ONSET ATRIAL FIBRILLATION: RESULTS FROM THE ORBIT-AF II REGISTRY (2016) (2)
Stroke prevention in atrial fibrillation (2012) (2)
Electropharmacologic effect of a standard dose of intravenous procainamide in patients with sustained ventricular tachycardia (2000) (2)
Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II) (2021) (2)
Role of Permanent Pacemakers in the Pharmacologic Therapy of Patients with Reentrant Tachyarrhythmias (1988) (2)
Open-Label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution for Acute Conversion of Recent-Onset, Symptomatic Atrial Fibrillation to Sinus Rhythm (2022) (2)
Intracellular Uptake of Agents That Block the hERG Channel Can Confound Assessment of QT Prolongation and Arrhythmic Risk. (2021) (2)
A new treatment for catastrophic arrhythmias (1995) (2)
Masquerading Bundle-Branch Block—Electrophysiological Correlation (1989) (2)
Therapeutic options for atrial fibrillation: Treatment strategies for the new millennium (2000) (2)
The Cardiac Arrhythmia Suppression Trial: How Has it Impacted on Contemporary Arrhythmia Management? (1990) (2)
Abstract 5335: Discordant T Wave and Mechanical Alternans in Left Ventricular Hypertrophy: Role of Late Sodium Current (2008) (2)
Effect of potassium-channel blockade on refractoriness and ventricular vulnerability during acute ischemia (1990) (2)
Dronedarone treatment following cardioversion in patients with atrial fibrillation/flutter: A post hoc analysis of the EURIDIS and ADONIS trials (2020) (2)
Antiarrhythmic drug therapy (2006) (2)
Differentiating electrophysiological effects and cardiac safety of drugs based on in vitro electrocardiogram: A blinded validation (2013) (2)
Detection of ECG effects of (2R,4R)-monatin, a sweet flavored isomer of a component first identified in the root bark of the Sclerochitin ilicifolius plant. (2016) (2)
New Antiarrhythmic Pharmacologic Therapies and Regulatory Issues in Antiarrhythmic Drug Development (2007) (2)
Stroke Prevention in Patients with Atrial Fibrillation (2018) (2)
State of Maryland pacemaker experience (1979-1980): conflicting views regarding the frequency of unnecessary pacemaker implants. (1983) (2)
DOES FRAILTY ALTER THE BENEFITS OF ORAL ANTICOAGULATION IN PATIENTS WITH ATRIAL FIBRILLATION (2017) (2)
Abstract 16415: Patterns of Atrial Fibrillation and Treatment Strategies Vary According to Provider Specialty Across Community Practice Settings: Findings From the ORBIT-AF Registry (2011) (2)
Does atrial fibrillation pattern affect stroke risk? Data dredging to help the clinician. (2015) (2)
Effects of the novel melanocortin receptor agonist bremelanotide on ambulatory blood pressure and heart rate in women with sexual dysfunction (2014) (2)
Prayer-meeting cardioversion. (1986) (2)
The Role of the Food and Drug Administration in Drug Development: On the Subject of Proarrhythmia Risk (2020) (2)
Clinical management of patients with nonsustained ventricular tachycardia: what do we really know? (1990) (2)
Abstract WP403: Factors Associated With Patient-Reported Shared Decision-Making for Stroke Prevention in Atrial Fibrillation (2019) (2)
Monomorphic Right Ventricular Tachycardia in a Patient with Mitral Valve Prolapse (1996) (2)
739 Cardiovascular (CV) assessments in short- and long-term Phase 3 mirabegron trials in patients with overactive bladder (OAB) (2013) (2)
Ablation Versus Drugs: What Is the Best First-Line Therapy for Paroxysmal Atrial Fibrillation?Response to Colleen M. Hanley, MD, Douglas Esberg, MD, FACC, FHRS, Peter R. Kowey, MD, FAHA, FHRS (2014) (2)
The Evolution of the One-Armed Bandit. (2019) (2)
I've fallen and I can't get up. (2003) (2)
Observing the Obvious. (2015) (1)
Cost-effectiveness analysis of antiarrhythmic agents (1991) (1)
Investigator-reported vs adjudicated cause of death in the TIOSPIR™ trial (2015) (1)
Abstract 130: Clinically Important Difference in the Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) Score: Results from the ORBIT-AF Registry (2016) (1)
Introduction to “Changing Perspectives in Cardiac Arrhythmia Control: Agents, Techniques, Goals, and Outcomes” (1995) (1)
Antiarrhythmic Medication for Atrial Fibrillation (AIM-AF) study: A physician survey of antiarrhythmic drug (AAD) treatment practices and guideline adherence in the EU and USA (2021) (1)
Abstract 16785: Atrial Fibrillation Clinical Phenotypes: A Cluster Analysis (2017) (1)
Asymptomatic ventricular ectopic activity and chronic ischemic heart disease. (1992) (1)
The Use of Omega-3 Polyunsaturated Fatty Acids (n-3 PUFAs) in Atrial Fibrillation (2016) (1)
Antiarrhythmic Medication for Atrial Fibrillation (AIM-AF) study: A physician survey of sotalol use and patient monitoring in the EU and USA (2021) (1)
Should Physicians Continue to Recommend Fish Oil for Patients with Atrial Fibrillation? (2012) (1)
Parenteral Antiarrhythmics for Life‐Threatening Ventricular Arrhythmias (1995) (1)
Abstract 141: Outcomes Associated with Temporarily Interrupting Anticoagulation in Outpatients with Atrial Fibrillation: Results from ORBIT-AF (2014) (1)
Born to Be Bradycardic? (2010) (1)
Outcomes of Cardiac Catheterization in Patients With Atrial Fibrillation on Anticoagulation in Contemporary in Practice (2020) (1)
NIFEDIPINE FOR HYPERTENSIVE EMERGENCIES. AUTHORS' REPLIES (1997) (1)
IMPACT OF DRONEDARONE STARTED RAPIDLY AFTER AMIODARONE DISCONTINUATION (2010) (1)
Pacing-induced angina pectoris and induction of ventricular arrhythmias in coronary artery disease. (1986) (1)
Residual stroke risk despite oral anticoagulation in patients with atrial fibrillation (2022) (1)
Marked QTc Reduction Immediately Following Direct Current Cardioversion of Atrial Fibrillation: Clinical Implications and Mechanisms. (2022) (1)
Initial Findings From the National Cardiovascular Data Registry of Atrial Fibrillation Ablation Procedures. (2023) (1)
Abstract 336: Real-World Experiences with Novel Anticoagulants for AF: Initial Insights from ORBIT-AF Phase II (2014) (1)
Relation of Antecedent Symptoms to the Likelihood of Detecting Subclinical Atrial Fibrillation with Inserted Cardiac Monitors. (2021) (1)
Abstract 18832: The ORBIT-AF Bleeding Score: a Simple Score to Assess Major Bleeding Risk in Atrial Fibrillation (2014) (1)
PREDICTORS OF PROGRESSION OF RECENTLY DIAGNOSED ATRIAL FIBRILLATION: RESULTS FROM THE RECORDAF – US COHORT (2012) (1)
GENETIC VARIANTS IN PATIENTS WITH BRUGADA SYNDROME (2016) (1)
P-238: Characteristics predicting blood pressure responses in 22,599 patients with hypertension and coronary artery disease: the International Verapamil SR/Trandolapril study (2002) (1)
Abstract 4634: Profile of Patients According to Chosen Therapeutic Strategy in the RecordAF Global Registry on Atrial Fibrillation Management (2008) (1)
Abstract 9992: Rhythm Control Versus Rate Control and Clinical Outcomes in Patients With Atrial Fibrillation: Results From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) (2015) (1)
Use of the HAVOC Score to Identify Patients at Highest Risk of Developing Atrial Fibrillation (2021) (1)
The geriatric paradox. (2008) (1)
PREVALENCE OF J WAVE AND EARLY REPOLARIZATION PATTERN AMONG HEALTHY TEENAGERS AND YOUNG ADULTS (2011) (1)
Real‐world algorithms for the optimal use of drugs and devices in the patient post myocardial infarction and the future of post myocardial infarction management (2005) (1)
The Relentless Pursuit of New Drugs to Treat Cardiac Arrhythmias. (2020) (1)
Left Ventricular Hypertrophy Increases Vulnerability to Bradycardia and D-Sotalol Induced Early Afterdepolarizations (1998) (1)
Abstract 189: Identifying Patients at Highest Risk of Developing Atrial Fibrillation and the Role of Remote Prior Stroke: Insights From the REVEAL AF Study (2018) (1)
Abstract 10368: Early Afterdepolarization Alternans Manifests T Wave Alternans in Left Ventricular Hypertrophy (2013) (1)
Antiarrhythmic drug interactions. (1995) (1)
Supraventricular Tachycardia: Drugs v Ablation (2007) (1)
Familial hypertrophic cardiomyopathy: cornering the rat. (2000) (1)
Why Did You Order That Echocardiogram? (2010) (0)
TREATMENT AND STROKE RISK IN LOW RISK CHA2DS2VASC ATRIAL FIBRILLATION PATIENTS: FINDINGS FROM THE ORBIT-AF REGISTRY (2016) (0)
Atrial Fibrillation Ablation Should Be First-Line Therapy in Heart Failure Patients: CON. (2019) (0)
In memoriam tribute to Dusan Z. Kocovic, MD. (2014) (0)
THE SHOCKING TRUTH: PHANTOM SHOCKS AS A MANIFESTATION OF PSYCHOLOGICAL PROBLEMS ASSOCIATED WITH ICD INSERTION (2018) (0)
REVERSE-USE DEPENDENCE OF ANTIARRHYTHMIC DRUGS: ROLE OF LATE SODIUM CURRENT. (2011) (0)
Lipids and Guidelines -- "Let Me Be Simple-Minded Doctor!!" LDL-C Less Than 70 mg/dL and Pay Attention to HDL (2020) (0)
Electrophannacologic Effect of a Standard Dose of Intravenous Procainamide in Patients with Sustained Ventricular Tachycardia (2008) (0)
Abstract 19349: Blood Pressure Control in Community Dwelling Patients with Atrial Fibrillation: Results from the ORBIT-AF Registry (2014) (0)
Abstract 12785: The American College of Cardiology's NCDR Afib Ablation Registry: A Summary of Initial Data Including Patient Characteristics, Procedural Characteristics, and Adverse Events (2020) (0)
AORTIC VALVE REPAIR/REPLACEMENT SHORTENS THE PROLONGED QT INTERVAL IN PATIENTS WITH ACQUIRED LONG QT SYNDROME ASSOCIATED WITH AORTIC VALVE STENOSIS (2016) (0)
Managing Atrial Fibrillation (New Antiarrhythmics and New Anticoagulants): Do They Represent Improvements over Previously Available Therapy? (2020) (0)
Medicine on Twitter: Boon or Bane? (2021) (0)
Antiarrhythmic Impact of Non-antiarrhythmic Cardiovascular Therapies (1998) (0)
P1903Efficacy and safety of dronedarone after recent cardioversion in patients with atrial fibrillation/flutter: a post-hoc analysis of the EURIDIS/ADONIS trials (2019) (0)
Ranolazine and Dronedarone in Combination Show Synergistic Effects on AF Suppression (2014) (0)
Abstract 13006: High Use of Concomitant Antiplatelet Therapy with Oral Anticoagulation in Patients with Atrial Fibrillation: Results from the ORBIT-AF Registry (2012) (0)
Abstract 16046: Clinical Action is Frequently Taken Following Detection of Previously Unknown Atrial Fibrillation by an Insertable Cardiac Monitor in High Risk Patients: The REVEAL AF Study (2017) (0)
Glass Half Empty? (2016) (0)
Abstract 16811: Who’s Left Behind? Characterization of Atrial Fibrillation Outpatients Eligible but Untreated With Oral Anticoagulation (2014) (0)
Abstract 302: Prevalence of Acquired Long QT Syndrome in Patients with Aortic Valve Stenosis (2016) (0)
Effect of Temporary Interruption of Warfarin Due to an Intervention on Downstream Time in Therapeutic Range in Patients With Atrial Fibrillation (from ORBIT AF). (2020) (0)
Abstract 057: Understanding of Treatment Strategies Among Patients Newly Diagnosed With Atrial Fibrillation: Findings From SATELITTE (2017) (0)
B-PO03-115 ANTIARRHYTHMIC MEDICATION FOR ATRIAL FIBRILLATION (AIM-AF) STUDY: A PHYSICIAN SURVEY OF ABLATION AND ANTIARRHYTHMIC DRUG USE IN THE USA AND EUROPE (2021) (0)
Perspective on Antiarrhythmic Drug Combinations. (2023) (0)
Thoroughly measuring the QT interval: can we find the shortcuts? (2011) (0)
Abstract 2669: Upregulation of Cardiac Sodium Channel Nav1.5 and Arrhythmias in Left Atrium in Left Ventricular Hypertrophy (2009) (0)
Assessing intracardiac thrombus prior to cardioversion: A story yet to be told (2018) (0)
A most remarkable person: Dr Bernard Lown. (2021) (0)
Cardioprotection : focus on calcium-channel blockers : medical panel discussion (1991) (0)
Abstract 303: Adoption of the Novel Oral Anticoagulant Dabigatran in Patients with Atrial Fibrillation Receiving Warfarin in Community Practice: Findings from ORBIT AF (2013) (0)
Atrial fibrillation: from rhythm control to outcome improvement (2011) (0)
The mechanism of the anti-fibrillatory effects of class III drugs. Experience with bretylium and clofilium (1984) (0)
Subject Index Vol. 111, 2008 (2008) (0)
The meta-analysis: supportive or illuminating? (2006) (0)
The impact of dronedarone on patients with atrial fibrillation and diabetes – a sub-analysis of the ATHENA and EURIDIS/ADONIS trials (2021) (0)
Chronic Coronary Artery Disease Predictors of Adverse Outcome Among Patients With Hypertension and Coronary Artery Disease (2006) (0)
Abstract 3492: Increased Late INa in Left Atrial Myocytes of Left Ventricular Hypertrophy Rabbits and its Role in Genesis of Atrial Early Afterdepolarizations (2008) (0)
PM025 A Severe Type of Long QT Syndrome and Cardiovascular Anomaly in a Homozygous Carrier of a Novel KCNH2 Mutation and Findings in Family Screening (2014) (0)
Abstract 152: Persistence of Warfarin versus Dabigatran Therapy in Patients with Atrial Fibrillation: Results from the ORBIT AF Registry (2015) (0)
RE: Tirosine kinase inhibitors adverse events (2014) (0)
Should we limit antiarrhythmic drug choice in patients with left ventricular hypertrophy? (2022) (0)
Efficacy and safety of dronedarone vs placebo in patients with atrial fibrillation or atrial flutter across a spectrum of renal function: post hoc analyses of the EURIDIS-ADONIS trials (2020) (0)
Abstract 10: Contraindications to Oral Anticoagulation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) (2013) (0)
Book Review Atrial Arrhythmias: State of the art (American Heart Association Monograph Series.) Edited by John P. DiMarco and Eric N. Prystowsky. 432 pp. Armonk, N.Y., Futura, 1995. $70. 0-87993-604-5 (1995) (0)
Back to the basics. (2017) (0)
Preface Advances in Antiarrhythmic Drug Therapy. (2010) (0)
Comprar Advances in Antiarrhythmic Drug Therapy, An Issue of Cardiac Electrophysiology Clinics | Peter R. Kowey | 9781437724295 | Saunders (2011) (0)
Sudden death in COPD: Investigator-reported and adjudicated causes of death in TIOSPIR (2017) (0)
Electrophysiolog ical Effects ofLeft Ventricular Hypertrophy Effect ofCalcium andPotassium ChannelBlockade (1991) (0)
P-430: All-cause mortality and cardioprotection: equivalent efficacy of a verapamil-SR strategy compared with an atenolol strategy in hypertensive patients with CAD: the international verapamil SR-trandolapril study (2004) (0)
CHARACTERISTICS OF AF PATIENTS WITH LARGE IMPROVEMENT IN SYMPTOMS AT ONE YEAR: SUPER-RESPONSE IN THE ORBIT-AF REGISTRY (2019) (0)
New Anticoagulants vs Warfarin: Take Your Choice (2020) (0)
P3797Increased risk of cardiovascular events and stroke among patients with atrial fibrillation and obstructive sleep apnea (2019) (0)
Efficacy and safety of dronedarone versus placebo in patients with atrial fibrillation stratified according to renal function: Post hoc analyses of the EURIDIS‐ADONIS trials (2022) (0)
Ambulatory Electrocardiographic Recording (2003) (0)
New antiarrhythmic therapies for atrial fibrillation (2011) (0)
Arrhythmias in the elderly. (1992) (0)
Cardiac Implantable Electrical Devices in the Elderly: A Promise of Prolonged Survival and an Improved Quality of Life (2007) (0)
THE IMPACT OF TEMPORARY INTERRUPTIONS OF WARFARIN ON DOWNSTREAM TIME IN THERAPEUTIC RANGE IN PATIENTS WITH ATRIAL FIBRILLATION: RESULTS FROM ORBIT AF (2019) (0)
Dronedarone New (2009) (0)
Health-Related Quality of Life in Patients With Atrial Fibrillation Treated With Rhythm Control Versus Rate Control (2014) (0)
Abstract 2848: Predictive Factors for Therapeutic Success in Patients With Recent-onset Paroxysmal and Persistent Atrial Fibrillation in the RecordAF Registry (2009) (0)
EFFICACY OF A CENTRALIZED, BLENDED ELECTRONIC, AND HUMAN INTERVENTION TO IMPROVE DOAC ADHERENCE: THE SMARTADHERE TRIAL (2019) (0)
No Reduction in Recurrent AF with Omega-3 Fatty Acids (2010) (0)
Abstract 15347: Symptom Status and Treatment Strategy in Contemporary Management of Atrial Fibrillation: Findings From the ORBIT-AF Registry (2011) (0)
Incidence of MI is equivalent with verapamil SR-based and atenolol-based strategies in patients with hypertension and CAD: the international verapamil SR-trandolapril study (2004) (0)
BLOOD PRESSURE AND RISK FOR STROKE OR BLEEDING EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION: RESULTS FROM THE ORBIT AF STUDY (2015) (0)
Abstract 15742: An Open-label, Multicenter Study of Flecainide Acetate Oral Inhalation Solution Shows Acute Conversion of Recent-onset, Symptomatic Atrial Fibrillation to Sinus Rhythm in a Dose- and Concentration-dependent Manner (2020) (0)
The tyranny of numbers, large and small (2017) (0)
Atrial fibrillation (2000) (0)
Corroboration Equals Collaboration. (2021) (0)
GW28-e0546 QT Measurement in the Presence of Atrial Fibrillation: Minimizing the Effects of RR Fluctuations on QT Interval (2017) (0)
Electrophysiologic effects of left ventricular hypertrophy in vivo: Effect of pharmacologic intervention (1990) (0)
Visits and Hospitalizations in Patients With an Implantable Cardioverter-Defibrillator in a Placebo-Controlled Clinical Trial (2016) (0)
The Role of and Selection Process for the New Anticoagulants in Nonvalvular Atrial Fibrillation (2020) (0)
Pharmacologic Management of Atrial Fibrillation (2002) (0)
SELECTION OF RATE VERSUS RHYTHM CONTROL FOR TREATMENT OF ATRIAL FIBRILLATION IN CLINICAL PRACTICE: RESULTS FROM THE ORBIT-AF REGISTRY (2012) (0)
5 LBBB : The ECG Patterns and Cardiac Function in Patients With and Without Coronary Artery Disease (2018) (0)
GW26-e2959 Genetic and Clinical Characteristics of Patients with Brugada Syndrome (2015) (0)
Abstract 283: Association of Body Mass Index with Outcomes in Patients with Atrial Fibrillation: Results From the ORBIT-AF Registry (2015) (0)
Follow up of patients with malignant ventricular arrhythmia value of medical therapy (1987) (0)
OUTCOMES OF CARDIAC CATH/PCI IN PATIENTS WITH AF: INSIGHTS FROM THE ORBIT II REGISTRY (2018) (0)
Baseline Characteristics of the Patients in the Two Treatment Groups * Placebo (2005) (0)
ASSOCIATION BETWEEN ELEVATED B-TYPE NATRIURETIC PEPTIDE, DISEASE PROGRESSION, AND CLINICAL OUTCOMES AMONG PATIENTS WITH ATRIAL FIBRILLATION (2018) (0)
Abstract 127: Differences in Care Patterns, Health Status, and Outcomes of Atrial Fibrillation in Patients With and Without Diabetes: Findings From the ORBIT-AF Registry (2017) (0)
ADHERENCE TO GUIDELINE RECOMMENDATIONS IN ATRIAL FIBRILLATION: FINDINGS FROM ORBIT-AF (2016) (0)
Unnecessary pacemaker implantation. (1983) (0)
LETTERS TO THE EDITOR (1983) (0)
Dronedarone versus sotalol in patients with atrial fibrillation: A systematic literature review and network meta-analysis. (2022) (0)
Abstract 18703: Impact of the 2014 Atrial Fibrillation Guideline on the Proportion of Patients Recommended for Oral Anticoagulation (2014) (0)
The results of this analysis also suggest the potential benefit of roflumilast on CV outcomes. Potential CV benefits of roflumilast should be evaluated in future controlled clinical trials. (2013) (0)
GW28-e0538 ECG Leads Selections for QT Measurement in the Presence of Atrial Fibrillation (2017) (0)
Abstract 14332: Factors Associated With Quality of Life in Atrial Fibrillation: Results From the ORBIT-AF Registry (2015) (0)
Man Helping Man: In Memoriam: A Tribute to Leonard S. Dreifus, MD. (2017) (0)
Impact of dronedarone on patients with atrial fibrillation and diabetes: A sub-analysis of the ATHENA and EURIDIS/ADONIS studies. (2022) (0)
Overview of the treatment of myocardial infarction: acute therapy and prophylaxis (1993) (0)
Abstract 13799: Comparing Incidence of Stroke and Non-CNS Embolism in Patients With Symptomatic and Asymptomatic Atrial Fibrillation: Insights From the ORBIT AF Registry (2017) (0)
Abstract 17152: Frequency and Management of Major Bleeding in Atrial Fibrillation Patients Treated With Warfarin and Non-vitamin K Oral Anticoagulants in Community Practice: Results From the ORBIT-AF II Registry (2015) (0)
Amiodarone for the Prevention of Shocks and Death in Patients with Implantable Cardioverter-Defibrillators: Hero or Villain? (2023) (0)
Abstract 308: Aortic Valve Stenosis Causes Both Delayed Ventricular Depolarization and Repolarization (2016) (0)
Cherry-picking Atrial Fibrillation Ablation Responders: Can Antiarrhythmic Drugs Help? (2021) (0)
NON VITAMIN K ORAL ANTICOAGULANTS ARE NOT ASSOCIATED WITH INCREASED RISK OF PERIOPERATIVE BLEEDING IN PATIENTS UNDERGOING CARDIAC SURGERY (2019) (0)
Hot topics: arrhythmias (2011) (0)
Darned If You Do…Darned If You Don't (2016) (0)
Chapter 32 – Postoperative Arrhythmias After Cardiac Surgery (2005) (0)
Abstract 15956: Triple Versus Dual Antithrombotic Therapy in Patients With Atrial Fibrillation and History of Coronary Artery Disease: Insights From the ORBIT-AF Registry (2013) (0)
The development of a mobile app‐focused deduplication strategy for the Apple Heart Study that informs recommendations for future digital trials (2022) (0)
Type a behavior and malignant ventricular arrhythmia (1990) (0)
Boldly Monitoring where Few People Have Monitored Before (2008) (0)
Abstract 10215: Predictors of Cause-Specific Hospitalization in US Outpatients With Atrial Fibrillation: Results From the ORBIT-AF Study (2013) (0)
Abstract 2701: Detection of Malignant Cardiac Arrhythmias: A Prospective Multi-center Randomized Study comparing Mobile Cardiac Outpatient Telemetry versus Standard Loop Event Monitor (2006) (0)
In reply. (2014) (0)
Abstract 14780: How Representative of the General Population Are the Cohorts Included in the Clinical Trials That Drive Our Guidelines? (2013) (0)
Peter Russell Kowey, MD: a conversation with the editor. (2014) (0)
Antiarrhythmic medication for atrial fibrillation (AIM-AF) study: a physician survey of antiarrhythmic drug (AAD) treatment practices and guideline adherence in Europe (2021) (0)
Long-term antithrombotic treatment for atrial fibrillation. Discussion (1998) (0)
Ischemia Versus Amiodarone Induced Polymorphic Ventricular Tachycardia (2002) (0)
NUISANCE BLEEDING IN ANTICOAGULATED PATIENTS WITH ATRIAL FIBRILLATION: INSIGHTS FROM THE OUTCOMES REGISTRY FOR BETTER INFORMED TREATMENT OF ATRIAL FIBRILLATION (ORBIT-AF) (2017) (0)
Cardiovascular Benefits of Icosapent Ethyl in Patients With and Without Atrial Fibrillation in REDUCE-IT. (2023) (0)
Abstract 15680: Sinus Node Dysfunction in Associated With Higher Symptom Burden and Increased Risk of Progression to Permanent Atrial Fibrillation: Results From ORBIT-AF Registry (2014) (0)
Bretylium, a Class III Antiarrhythmic, Returns to the Market. (2020) (0)
A Review of the Cardiovascular Safety of Prucalopride in Patients with Chronic Idiopathic Constipation. (2023) (0)
Advances in Antiarrhythmic Drug Therapy, An Issue of Cardiac Electrophysiology Clinics (2011) (0)
Abstract 17225: Therapeutic Strategies Following Major Bleeding in Atrial Fibrillation: Findings From ORBIT-AF (2015) (0)
Adverse Effects of Amiodarone at Low Doses (1989) (0)
Cardioversion of obese patients: What is the weight of evidence? (2018) (0)
Gaps in the ARB Knowledge Base: Are ARBs Effective Anti–Atrial Fibrillation Agents? (2009) (0)
Pacemaker therapy. (1985) (0)
Human Basic Fibroblast Growth Factor Induces Angiogenesis in Hen Eggs and Rat Hearts (1999) (0)
Abstract P128: Inhomogeneous Upregulation of Sodium Channel Nav1.5 and Its Role in Discordant T Wave and Mechanical Alternans in Left Ventricular Hypertrophy (2009) (0)
Contents Vol. 111, 2008 (2008) (0)
Abstract 10986: Use of the “Pill in the Pocket” Approach for Atrial Fibrillation Termination as Determined from the Antiarrhythmic Medication for Atrial Fibrillation (AIM-AF) Study: A Physician Survey on the Prescription of Antiarrhythmic Drugs in the USA and Europe (2021) (0)
Cardiovascular Safety Profile of Dapoxetine during the Premarketing Evaluation (2011) (0)
P1034Impact of ablation status on the efficacy and safety of dronedarone in patients with atrial fibrillation/flutter: a post-hoc analysis of the ATHENA trial (2019) (0)
Abstract 17202: Comparative Performance of the R2Chads2, Chads2, and Cha2Ds2-vasc Scores in Atrial Fibrillation (2015) (0)
Nifedipine for Hypertensive Emergencies-Reply (1997) (0)
Heart Block/Cardiac Pacing (1993) (0)
“Doctor, Why Didn't You Tell Me About This Before the ICD?” (2006) (0)
Smoothing the Bumpy Road to Antiarrhythmic Drug Development. (2015) (0)
Heart Failure is Associated With Worse Quality of Life and Survival But Similar Stroke Risk in Atrial Fibrillation (2015) (0)
Increased susceptibility to ventricular arrhythmia at low-normal and moderately-low levels of extracellular potassium in Catecholaminergic Polymorphic Ventricular Tachycardia. (2022) (0)
SIMPLE PREDICTION OF LONG-TERM MORTALITY AMONG HYPERTENSIVE PATIENTS WITH CORONARY ARTERY DISEASE: NEW DATA FROM AN EXTENDED FOLLOW-UP OF THE INTERNATIONAL VERAPAMIL-SR/TRANDOLAPRIL STUDY (INVEST) (2012) (0)
Optimal management of the patient post myocardial infarction with or without heart failure: Introduction (2005) (0)
Coronary arteriography for whom? (1980) (0)
ASSESSMENT OF STROKE RISK IN ATRIAL FIBRILLATION: PHYSICIAN ESTIMATE VERSUS CHADS2 RISK SCORE: RESULTS FROM ORBIT-AF (2014) (0)
Role of Antiarrhythmic Drugs: Frequent Implantable Cardioverter- Shocks, Risk of Proarrhythmia, and New Drug Therapy (2011) (0)
Abstract 424: Fish Oils Reduce the Risk of Stroke in Patients with Hypertension (2012) (0)
A Practice of Cardiac Pacing (1987) (0)
Does "anti-lipid" also mean "anti-arrhythmic"? (2005) (0)
Journal Pre-proof Residual Stroke Risk Despite Oral Anticoagulation in Patients with Atrial Fibrillation (2022) (0)
Abstract 77: Balancing Risks and Benefits of Anticoagulation Therapy in Atrial Fibrillation in Community Practice: Results from the ORBIT-AF Registry (2012) (0)
Factor XI/XIa Inhibitors…Here We Go Again! (2023) (0)
OUTCOMES IN PATIENTS WITH A FAMILY HISTORY OF ATRIAL FIBRILLATION: FINDINGS FROM THE OUTCOMES REGISTRY FOR BETTER INFORMED TREATMENT OF ATRIAL FIBRILLATION (2015) (0)
Abstract 16058: Comparing Symptoms and Quality of Life in Women and Men with Atrial Fibrillation: Results from the Orbit-AF Registry (2012) (0)
CARDIOVERSIONS AND ATRIAL FIBRILLATION: PATIENT OUTCOMES IN THE UNITED STATES: DATA FROM ORBIT-AF (2014) (0)
One Small Step (2009) (0)
Predictors of dronedarone plasma drug concentrations and effect on atrial fibrillation/atrial flutter recurrence: Analyses from the EURIDIS and ADONIS studies (2022) (0)
J-SHAPED RELATIONSHIP BETWEEN RESTING HEART RATE AND MORTALITY IN PATIENTS WITH PERMANENT AF: RESULTS FROM THE OUTCOMES REGISTRY FOR BETTER INFORMED TREATMENT OF ATRIAL FIBRILLATION (ORBIT-AF) (2015) (0)
Atrial Fibrillation in the Post-AFFIRM Era (2006) (0)
Comprar Cardiac Arrhythmias, Pacing and Sudden Death | Peter Kowey | 9783319579986 | Springer (2017) (0)
The reply. (2013) (0)
Out of phase T wave alternans in left ventricular hypertrophy: its role in ventricular arrhythmogenesis (2002) (0)
Abstract 325: Paradoxical Relationship Between Bleeding Risk, Stroke Risk, and Time in Therapeutic Range for Atrial Fibrillation Patients on Warfarin: Data from ORBIT-AF (2014) (0)

This paper list is powered by the following services:

Other Resources About Peter R. Kowey

en.wikipedia.org

What Schools Are Affiliated With Peter R. Kowey?

Peter R. Kowey is affiliated with the following schools:

Peter R. Kowey's Academic­Influence.com Rankings

Peter R. Kowey's Degrees

Why Is Peter R. Kowey Influential?

Peter R. Kowey's Published Works

Published Works

Other Resources About Peter R. Kowey

What Schools Are Affiliated With Peter R. Kowey?

Peter R. Kowey's AcademicInfluence.com Rankings